Replimune Group, Inc. (NASDAQ:REPL) Sees Large Growth in Short Interest

Replimune Group, Inc. (NASDAQ:REPL) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, a growth of 16.7% from the January 15th total of 7,260,000 shares. Based on an average daily trading volume, of 885,200 shares, the days-to-cover ratio is presently 9.6 days.

Replimune Group Stock Performance

Shares of REPL stock traded down $0.19 during trading hours on Monday, reaching $14.10. The company had a trading volume of 431,744 shares, compared to its average volume of 790,791. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The business has a fifty day moving average price of $12.54 and a 200-day moving average price of $11.74. The firm has a market cap of $964.72 million, a PE ratio of -4.62 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Sell-side analysts predict that Replimune Group will post -2.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Replimune Group in the 3rd quarter worth approximately $251,000. Creative Planning raised its position in Replimune Group by 28.7% in the third quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after acquiring an additional 4,699 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after acquiring an additional 5,926 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Replimune Group during the 3rd quarter worth $222,000. Finally, LMR Partners LLP grew its position in shares of Replimune Group by 145.8% during the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after acquiring an additional 48,920 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on REPL shares. HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group upped their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets lifted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $19.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.